<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547530</url>
  </required_header>
  <id_info>
    <org_study_id>UW19-411</org_study_id>
    <nct_id>NCT04547530</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D Supplementation in Live Birth Rate of in Vitro Fertilization Outcome</brief_title>
  <official_title>A Randomized Double-blind Placebo-controlled Trial to Investigate the Effect of Vitamin D Supplementation in Live Birth Rate of in Vitro Fertilization Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kwong Wah Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized-controlled trial evaluating the effect of the use of vitamin D&#xD;
      supplementation on the live birth rate in women undergoing in vitro fertilization (IVF). The&#xD;
      hypothesis is that administration of vitamin D can increase the live birth rate for women&#xD;
      undergoing IVF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing IVF treatment cycle at Queen Mary Hospital and Kwong Wah Hospital will be&#xD;
      invited to participate in this study. Participating subjects will be randomized into either&#xD;
      (i) vitamin D or (ii) placebo group in a 1:1 allocation ratio by computer-generated random&#xD;
      numbers one month before IVF.&#xD;
&#xD;
      Subjects allocated to the vitamin D group will take vitamin D 50,000IU per week from&#xD;
      recruitment for 4 weeks, followed by 50,000IU once every 2 weeks throughout the IVF cycle&#xD;
      until fetal viability is confirmed at 6 weeks (if pregnant), after which they will be&#xD;
      switched to Materna. If not pregnant, they will continue Vitamin D 50,000IU once every 2&#xD;
      weeks until 6 months from randomization, during which they can undergo frozen-thawed embryo&#xD;
      transfer.&#xD;
&#xD;
      Subjects allocated to the placebo group will take placebo tablets which will be identical to&#xD;
      the active drug. If pregnant and fetal viability is confirmed at 6 weeks, they will be&#xD;
      switched to Materna. If not pregnant, they will continue the placebo tablets until 6 months&#xD;
      from randomization, during which they can undergo frozen-thawed embryo transfer.&#xD;
&#xD;
      The clinician and patients will both be blinded to the randomization throughout the course of&#xD;
      treatment. The live birth rate of the two groups will be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>10 months</time_frame>
    <description>per embryo transfer procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative pregnancy rate within 6 months of randomization</measure>
    <time_frame>6 months</time_frame>
    <description>within 6 months of randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and follicular vitamin D levels</measure>
    <time_frame>6 weeks</time_frame>
    <description>vitamin D levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>pregnancy test positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>10 weeks</time_frame>
    <description>Presence of intrauterine gestational sac on ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Viable pregnancy beyond 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obstetrics complications</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1150</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D 50,000IU per week for 4 weeks from recruitment, followed by 50,000IU per week every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.&#xD;
If not pregnant, to continue vitamin D 50,000IU once every 2 weeks until 6 months from recruitment.&#xD;
The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets identical to the active drug for 4 weeks from recruitment, followed by placebo tablets once every 2 weeks throughout the IVF cycle. Subjects to stop own supplements and folic acid will be provided. If pregnant and fetal viability confirmed at 6 weeks gestation, switch to Materna until delivery.&#xD;
If not pregnant, to continue placebo tablets once every 2 weeks until 6 months from recruitment.&#xD;
The rest of the IVF, embryo transfer procedure and antenatal care will be the same as usual practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>as above</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>as above</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infertile women undergoing IVF&#xD;
&#xD;
          -  Aged between 18 and 43 years old, inclusive, at the time of signing informed consent&#xD;
&#xD;
          -  Having given voluntary written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Already taking vitamin D&#xD;
&#xD;
          -  Undergoing preimplantation genetic testing&#xD;
&#xD;
          -  Use of donor oocytes or donor embryos&#xD;
&#xD;
          -  Presence of hydrosalpinx not corrected surgically&#xD;
&#xD;
          -  Active tuberculosis/ receiving therapy for tuberculosis&#xD;
&#xD;
          -  History of any medical condition or medications that may predispose to vitamin D&#xD;
             sensitivity, altered vitamin D metabolism and/or hypercalcemia, including history of&#xD;
             renal/ureteral stones, parathyroid disease, renal or liver failure, current use of&#xD;
             anticonvulsants, current use of steroid&#xD;
&#xD;
          -  Allergy to vitamin D&#xD;
&#xD;
          -  Abnormal serum calcium values&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Ka Yee Ko, MBBS</last_name>
    <phone>2255 4647</phone>
    <email>jenko@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kwong Wah Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <contact>
      <last_name>Shui Fan Lai, MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital, University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Ka Yee Ko, MBBS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

